Sue, Author at InSphero


April 16, 2021
Vitruvian Rat and Man

Measuring Aspartate Transaminase (AST) In Vitro – Closing the Gap to Clinical Data

InSphero's Scientific Ambassador Sue Grepper, Ph.D., highlights how to recapitulate clinically observed increases of Aspartate Transaminase (AST) levels in preclinical in vitro safety studies. If you have experienced a clinical […]
May 1, 2020
NASH model treatments

Experimental Design Considerations for NASH Drug Screening

An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
September 23, 2019
Microtissue illustration

Can an in vitro NASH endpoint be truly predictive of the in vivo response?

Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019
Mouse on a plate

Are Animal NASH models slowing us down?

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog.  She […]
June 18, 2018

Improving preclinical models for NASH Drug Discovery

In honor of the inaugural International NASH Day, Insphero explains why we need better preclinical models for non-alcoholic steatohepatitis (NASH) disease drug discovery. Non-alcoholic fatty liver disease (NAFLD) is one of […]